

The Hepatic Hijack: How Pregnancy Affects Liver Disease: Case Series

Dr. Koluguri Bhavana¹, Dr Sheela S R²

¹Post Graduate, Department of Obstetrics and Gynaecology, Sri Devaraj Urs Medical College and Research Centre

Tamaka, Kolar, Karnataka, India

Email: [bhavanakoluguri1234\[at\]gmail.com](mailto:bhavanakoluguri1234[at]gmail.com)

Professor, Department of Obstetrics and Gynaecology, Sri Devaraj Urs Medical College and Research Centre, Tamaka, Kolar, Karnataka, India

Corresponding Author Email: [drsrsheela\[at\]gmail.com](mailto:drsrsheela[at]gmail.com)

Abstract: Liver diseases in pregnancy may be categorized into liver disorders that occur only in the setting of pregnancy and liver diseases that occur coincidentally with pregnancy. Out of all diseases Intra hepatic cholestasis of pregnancy is most commonly seen usually in third trimester and resolves post delivery with medication. Intrahepatic cholestasis of pregnancy (ICP) is a liver disease specific to pregnancy. ICP is usually seen during the second or third trimester of pregnancy and improves automatically after delivery. ICP has been identified worldwide, but its prevalence varies considerably depending on country and ethnicity. The role of clinical suspicion, early diagnosis, variable presentation of patient, proper management and proper followup is being studied in this case series. **Methods:** This study was a retrospective observational study, carried out in the R L jalappa hospital and research centre kolar karnataka. Status of women who had liver diseases during their pregnancy. This was studied between December 2024 and February 2025 after taking exclusion and inclusion criteria into consideration. Following details were noted which included clinical history, examination, investigations and treatments including operative reports and management were reviewed and surgical outcomes were obtained. **Results:** 4 cases of liver diseases in pregnant females were identified from Dec 2024 to Feb 2025. 4 patients were diagnosed as Intrahepatic cholestasis of pregnancy. All the 4 patients presented with complaints such as itching all over body more on palms and soles and pain in the right upper quadrant of abdomen. All the 4 patients were diagnosed by evaluating serum LFT and serum bile acids levels. All patients were treated by giving Tab. UDILIV 300MG Orally BD, Tab RIFAGUT 550 MG RT BD, HEPAMER Q SACHETS orally TID along with intake of plenty of oral fluids. Usually by the end of 1 week or by 10 days of delivery of fetus which is either by vaginal delivery or caesarean section majority of the symptoms subsided. **Conclusion:** Intrahepatic cholestasis of pregnancy is a common hepatic disorder associated with pregnancy. Pruritus, developing most commonly in third trimester of pregnancy, is the most specific clinical symptom. The resolution of symptoms is seen most commonly after the delivery. Laboratory diagnosis is mainly based on elevated total Liver function tests especially ALT and serum bile acids levels in the maternal blood. The mainstay of therapeutic management consists in the reduction of maternal symptoms by using Urso deoxy cholic acid. In my study there is significant reduction of maternal symptoms after delivery of fetus and usage of tablet ursodeoxy cholic acid. Maternal outcomes have good prognosis but fetal outcomes can be improved by timely and effective intervention which is usually possible in tertiary care centres as shown in my study.

Keywords: Intrahepatic cholestasis, pregnancy related liver disorder, maternal pruritus, ursodeoxycholic acid therapy, fetal outcome management

1. Introduction

Liver dysfunction during pregnancy can be caused by conditions that are specific to pregnancy or by liver diseases that are not related to pregnancy itself¹. Liver diseases in pregnancy may be categorized into liver disorders that occur only in the setting of pregnancy and liver diseases that occur coincidentally with pregnancy. Hyperemesis gravidarum, preeclampsia/eclampsia, syndrome of hemolysis, elevated liver tests and low platelets (HELLP), acute fatty liver of pregnancy, and intrahepatic cholestasis of pregnancy are pregnancy-specific disorders that may cause elevations in liver tests and hepatic dysfunction. Out of all diseases Intra hepatic cholestasis of pregnancy is most commonly seen usually in third trimester and resolves post-delivery with medication². They are caused by either a disorder that is unique to pregnancy or an acute or chronic liver disease that already exists or coincidentally develops as a comorbidity of pregnancy. Liver diseases unique to pregnancy include hyperemesis gravidarum; hypertensive disorders of pregnancy, such as pre-eclampsia/eclampsia; hemolysis, elevated liver enzymes, and low platelet count syndrome; Intrahepatic cholestasis of pregnancy; and acute fatty liver of

pregnancy³. Pregnancy directly affects the physiology of the liver and hepatic disorders can adversely affect pregnancy outcomes. In developed countries, approximately 3% of pregnant women are affected by some form of liver disease during their pregnancy⁴. Some of these conditions can be fatal for both the mother and fetus. It is, therefore, important to determine the underlying cause of abnormal liver function, enabling prompt management to reduce morbidity and mortality⁵. Before considering the diagnosis of pregnancy-specific liver disorders, liver disorders that are not related to pregnancy must be excluded⁶. The aim of this article is to provide a systematic approach to pregnancy-specific liver disorders. Prompt diagnosis and management of liver diseases in pregnancy, while very challenging, is extremely important, as they might cause adverse maternal and fetal outcomes.

ICP typically appears in the third trimester of pregnancy, although it can present much earlier in some women. The most common symptom present is pruritus, which varies in intensity in each individual patient⁷. Other symptoms include pain in the right upper quadrant, pale stool, and dark urine. Elevated serum bile acids are used to make the diagnosis. Other cholestatic laboratory values may be elevated,

Volume 14 Issue 4, April 2025

Fully Refereed | Open Access | Double Blind Peer Reviewed Journal

www.ijsr.net

including aspartate aminotransferase, alanine transaminase, alkaline phosphatase, gamma-glutamyl transferase, and bilirubin. ICP increases the risk of stillbirth for the baby, NICU care. In most women, pruritus resolves after delivery⁸. Affected individuals have a defect involving the excretion of bile salts, which leads to increased serum bile acids. These are deposited within the skin, causing intense pruritus. The cause of ICP is unknown but is thought to be multiple factors with genetic, hormonal, and environmental involvement⁹. The correlation of increased maternal serum bile acids concentrations with intrauterine fetal demise is consistently seen in retrospective studies of females with intrahepatic cholestasis of pregnancy. Most patients with ICP do not develop clinical jaundice. The liver function predominantly shows features of cholestasis. The most characteristic laboratory abnormality is high serum bile acid levels ($\geq 10 \mu\text{mol/L}$) which may be elevated up to 100-fold. Severe obstetric cholestasis is defined by levels $>40 \mu\text{mol/L}$. Other findings are conjugated hyperbilirubinemia, increase in serum ALP, gamma glutamyl

transferase (GGT) and serum aminotransferases are normal or only minimally elevated¹⁰. The synthetic function of the liver and the liver architecture remains unaltered. ICP progresses until the time of delivery. Pruritus disappears within 24-48 hours postpartum, but biochemical and histological abnormalities may take weeks to months to resolve. ICP may reoccur in next pregnancies in 60-70%, although not necessarily as severe as the first episode. UDCA is the best available therapeutic agent which relieves maternal symptoms¹¹. Managing these patients is of paramount importance to reduce the maternal and foetal morbidity and mortality. Non-pharmacological management includes keeping patients well-hydrated, use of cotton cool and wearing loose clothes and avoiding high-fat diet. Antihistamines are usually not effective¹². Ursodeoxycholic acid is currently the only effective medicine in dose of 10-15 mg/day in 2 to 3 doses to prevent maternal morbidity and mortality. Frequency of intrahepatic cholestasis of pregnancy. The drug should be given 2 to 3 weeks prior to delivery. Patient usually has relief within 2 weeks¹³.

2. Methods

Study Design: Retrospective Observational Study.

Source of Data: The medical records of liver diseases in pregnancy admitted to R. L. Jalappa Hospital & Research Centre, Kolar will be reviewed and assessed as part of the study.

Objectives:

To study the liver diseases in pregnancy specifically Intrahepatic cholestasis of pregnancy and to study the management of liver disease and their outcome in pregnancy

Inclusion Criteria: Pregnant Women who had deranged LFT in present pregnancy.

Exclusion Criteria: Pregnant Women with already previous liver diseases.

Method of Collection: The data from the medical records will be entered into a proforma for the study. It includes the

demographic and patient identification information such as name, age, and information about admission such as medical diagnosis, date of admission, and length of hospital stay and clinical features, investigations, management, complications and follow up with Liver function tests and bile acid levels.

Method of Assessment: All the case sheets of the women who are diagnosed with liver disease in pregnancy at R.L. Jalappa Hospital and Research Centre under the aegis of SDUAHER from December 2024 to February 2025 will be reviewed.

3. Results

Case 1: A 23 year old Primigravida with 32 weeks of gestation, referred from District government Hospital in view of intrauterine demise with deranged LFT. Patient presented to RL Jalappa hospital with complaints of fatigability since 2 days. Patient has history of fever and was treated conservatively. On arrival to casualty, her GCS was 9/15, PR:108bpm, BP:120/80mmhg, SPO2: 97% on room air. Patient was pale, icteric with pedal edema. Relevant investigations done and reported Hb as 8.5gm, WBC-77Th/mm3, PLT: 38th/mm3, urea: 147mg/dl, creat: 6mg/dl. Patient was shifted to ICU in view of drop in GCS with sepsis with MODS. Obstetric scan done and reported as Intrauterine fetal demise. Patient had a spontaneous preterm vaginal delivery of dead female baby of weight 1.56kg at 3:15pm on 12/03/2025. Physician opinion taken in view of sepsis and patient was started on higher antibiotics. Nephrology opinion taken in view of deranged RFT and strict I/O monitoring done. Blood culture and urine culture done and reported as no growth. Serial LFT, RFT monitoring was done and diagnosed as Intrahepatic cholestasis of pregnancy. Patient had one episode of GTCS type of convulsion associated with frothing and uprolling of eyes. Patient was resuscitated and MRI BRAIN was done and reported as metabolic encephalopathy with pituitary apoplexy. Sodium bicarbonate IV correction was given in view of metabolic acidosis. 6 platelets, 1 FFP, 2 PINTS PRBC TRANSFUSED. Patient had bilateral lower limb swelling for which venous Doppler was done and reported as normal. Patient was treated with Tab UDILIV 300MG Orally BDx 10 days, Tab RIFAGUT 550 MG RT BD X 12 DAYS, HEPAMER Q SACHETS orally TID x 12 days. Regular vitals monitoring was done. Serial CBC, RFT, LFT monitoring done and patient improved symptomatically. Patient was shifted out of ICU on Post natal day 5. On PND 10 patient developed fever and fever profile was sent, urine routine and blood culture sent and reported as no growth of organisms. Regular vitals monitoring done and stable. Regular temperature monitoring done. Regular perineal care was given and wound was healthy. Patient was symptomatically better and discharged from the hospital on post natal day 15 and advised for regular followup.

Case 2: A 29 year old G3P1L1A1 with 36 weeks 2 days gestational age 9 months of amenorrhea appreciating fetal movements well came with itching all over the body with severity in palms and soles during night since 2 months. Relevant investigations sent and Hb reported as 10.1gm% and increased serum ALP and GGT levels seen along elevated serum bile acids. Physician opinion was taken in view of deranged LFT values and diagnosed as Intrahepatic

cholestasis of pregnancy. Patient had a Misoprostol induced vaginal delivery of a single live term male baby of birth weight of 2.74kgs at 8:57 AM on 21/03/2025. Baby cried after suction and stimulation. Meconium stained liquor noted. APGAR 1' 6/10 & 5'8/10. Baby shifted to NICU in view of Respiratory distress. patient was treated with TAB. UDILIV 300 mg orally BD. Regular perineal care given, episiotomy wound healthy, Patient was stable and hence being discharged on post natal day 10 and advised for regular follow- up.

Case 3: A 24 year-old G2P1L1 with 39 weeks of gestational age appreciating fetal movements well, came with complaints of Itching all over body severe in palms and soles for 1 month and pain in the right upper quadrant of abdomen since 3 days. Relevant investigations were sent and Hb was reported as 11.7 gm% and deranged LFT such as elevated ALT levels. Patient underwent Elective LSCS and Extracted by vertex a single live term Female baby of birth weight 2.96KGS at 6:34PM on 06/03/25 . Baby cried immediately after birth. Thick Meconium-stained liquor noted. APGAR 1'6/10 & 5'8/10. Baby shifted to NICU in view of Respiratory distress., Repeat LFT levels done and ALT levels remains elevated hence physician opinion taken and diagnosed as Intrahepatic cholestasis of pregnancy. Patient was treated with Tab UDILIV 300MG Orally BD, Tab RIFAGUT 550 MG RT BD. suture removal done on post operative day 13 wound healthy. Patient was symptomatically stabilized and hence being discharged and advised for regular follow-up.

Case 4: A 30 year old G2P1L1 with 9 months of amenorrhoea, appreciating fetal movements well came with complaints of intense itching all over body and more severe on palms and soles especially during nights. Patient has history of dark urine since 15 days. On arrival patient vitals were stable. Patient was icteric with pedal edema. Relevant investigations were sent and hb reported as 9gm, WBC was 16Th/mm3, PLT: 158th/mm3 urea: 175mg/dl and creat: 4.6mg/dl. Investigations revealed deranged LFT. Obstetric scan done and reported as single live intrauterine gestation with 39 weeks 2days with AFI-11cm and EFW 2.9kgs. She had A Foleys and misoprostol Induced vaginal delivery of a single live male baby of birthweight 2.76kg at 5:35Am on 19/02/2025. Physician opinion was taken in view of deranged LFT and increased bilirubin levels and elevated bile acids levels and diagnosed as Intrahepatic cholestasis of pregnancy and started on higher antibiotics. Patient had 2 episodes of GTCS type of convulsions not associated with frothing and no uprolling of eyes. Patient was resuscitated and MRI BRAIN was done which reported as Posterior reversal encephalopathy syndrome. IV Mgso4 was given for 24 hours and then patient was started on antihypertensives in view of increased bp readings after delivery. Regular vitals monitoring done. Serial CBC, RFT, LFT monitoring done and patient improved symptomatically. Repeat LFT levels done and ALT levels remained elevated hence physician opinion taken and diagnosed as Intrahepatic cholestasis of pregnancy. Patient was given Tab UDILIV 300mg Orally BD, Tab RIFAGUT 550mg RT BD. Urine routine showed protein 3+ cells for which physician opinion was taken and advice was followed. Regular vitals monitoring done and stable. Strict bp monitoring done and antihypertensives tapered slowly. Regular perineal care given, episiotomy wound healthy,

Patient is now stable and hence being discharged on post natal day 13 and advised for regular followup.

4. Discussion

Intrahepatic cholestasis of pregnancy is an obstetric cholestasis or jaundice of pregnancy. It frequently develops in late trimester of pregnancy in individuals who are predisposed and it is the most common pregnancy-related liver disorder¹⁴. ICP is a pregnancy specific liver disorder seen in third trimester of pregnancy and is associated with increased numbers of adverse neonatal outcomes. Though, maternal consequences of ICP are benign; however, clear association is seen amongst ICP and higher prevalence of fetal distress, premature delivery, and sudden intrauterine demise and maternal morbidity if left untreated. Most common symptom was pruritus and patients developed pruritus between 32weeks to 36 weeks of gestation¹⁵. A high rate of preeclampsia and convulsions was noted. In Intra hepatic cholestasis of pregnancy generalised pruritus is the first clinical symptom¹⁶. Pruritus can be mild and bearable for some females, but can also be very grave and unbearable. It may also lead to interfere the patient's sense of well-being by insomnia, mental sufferings and even increased suicidal tendencies¹⁷. Pruritus is more grave in later half of the day mostly in nights, more seen in the palms of the hands and soles of the feet. Moderately elevated levels of conjugated bilirubin occurs in 10- 15% patients presents as mild jaundice. Jaundice can sometimes be the initial symptom but usually develops one to four weeks after the onset of pruritus¹⁸. Subclinical steatorrhea is usually seen in patients with poor fat absorption which can in turn cause vitamin K deficiency leading to prolonged PT (prothrombin time) and PPH(post-partum haemorrhage). Women with history of intrahepatic cholestasis of pregnancy, even in first degree relatives tend to have higher chances of developing gall stones and cholecystitis. Increased levels of serum bile acids and serum aminotransferase levels are seen as most common biochemical derangements¹⁹. Serum total bile acids levels may be elevated by 10 folds. If women's fasting serum bile acid levels are more than 40 µmol/L it most commonly leads to fetal complications. In intrahepatic cholestasis of pregnancy, cholic acid levels are more increased than chenodeoxycholic acid. Aminotransferases levels are also increases two –ten-fold more than the average in 26% of females with pruritus, and can exceed to 1000 U/L in rare circumstances. Serum aminotransferases help in better follow up of the patients once we start treatment with ursodeoxycholic acid rather with fasting serum bile acid levels (total) in patients which firstly are elevated secondary to elevated levels in serum urodeoxycholic acid (UDCA) levels²⁰. Due to increased in levels of placenta isoenzyme, increased levels of serum alkaline phosphatase can be difficult to recognize.

In present study, all of the following patients had their symptom onset during the 32-36 weeks of gestation. Majority of symptoms occurred in the third trimester in 90% of the women presenting after 30 weeks of gestation²¹. According to the statistics that the incidence of hyaline membrane disease leading to respiratory depression in neonates of mothers diagnosed with intrahepatic cholestasis of pregnancy is double than in neonates of normal population²². Respiratory

depression in neonate can also be due to pre-term delivery, but based on study of fluid taken from bronchoalveolar lavage of newborn of mothers with intrahepatic cholestasis of pregnancy it demonstrates that respiratory depression is specifically associated with ICP²³. It has been postulated that increased levels of serum bile acids can lead to depletion of surfactant in the alveoli of lungs of fetus. The chances of fetal affection in ICP is more than that of normal population. In our study 1 patient had intrauterine fetal demise²⁴. Lately management of intra hepatic cholestasis of pregnancy is induction of labor at 36–38 weeks period of gestational age, mostly used for patients with serum bile acids 40 µmol/L had higher fetal risk of premature delivery, birth asphyxia, meconium staining of liquor amnii, and patients with serum bile acids ranging from 10–39 µmol/L had decreased risk²⁵.

In this study, no clinical or biochemical predictors association with increased fetal affection were significant enough. This can be due to contrast in basic practice, where we essentially terminate pregnancy in females diagnosed ICP at approx. 37 weeks gestational age²⁶.

5. Results

ICP is frequent cause of hepatic deterioration in pregnancy. Maternal morbidity is increased in terms of fetal distress and fetal demise and discomfort due to pruritus. Maternal cholestasis is transient with resolved after delivery. ICP is associated with adverse perinatal outcome. There is higher risk of meconium stained liquor, birth asphyxia, and sudden intrauterine demise at term as evidenced in this study.

6. Conclusion

Intrahepatic cholestasis of pregnancy is a common hepatic disorder associated with pregnancy. Pruritus, developing most commonly in third trimester of pregnancy, is the most specific clinical symptom. The resolution of symptoms is seen most commonly after the delivery. Laboratory diagnosis is mainly based on elevated total Liver function tests especially ALT and serum bile acids levels in the maternal blood. The mainstay of therapeutic management consists in the reduction of maternal symptoms by using Urso deoxy cholic acid. In my study there is significant reduction of maternal symptoms after delivery of fetus and usage of tablet ursodeoxy cholic acid. Maternal outcomes have good prognosis but fetal outcomes can be improved by timely and effective intervention.

Acknowledgements: The author would like to thank her guide, and patients who cooperated throughout the study.

Declarations:

Funding: No funding sources.

Conflict of interest: None declared.

Ethical approval: The study was approved by the Institutional Ethics Committee.

References

- [1] Viswanathan L, Sthaneshwar P, Razali N, Thambiah SC. Diagnosis and Management of Intrahepatic Cholestasis of Pregnancy-A Retrospective Clinical Audit. *Malaysian Journal of Medicine & Health Sciences*. 2022 Dec 4;18.
- [2] Bartolone S, Alexis R. Intrahepatic cholestasis of pregnancy: an autobiographical case report. *Cureus*. 2022 Jan 18;14(1).
- [3] Bartolone S, Alexis R. Intrahepatic cholestasis of pregnancy: an autobiographical case report. *Cureus*. 2022 Jan 18;14(1).
- [4] Muresan D, Ona D, Cruciat G, Rotar I, Stamatian F. Recurrent intrahepatic cholestasis of pregnancy. A case report. *J Gastrointest Liver Dis*. 2008 Sep 1;17(3):323-5.
- [5] Kumar S, Puri P, Gujral K. Intrahepatic cholestasis of pregnancy. *Current Medicine Research and Practice*. 2018 Nov 1;8(6):230-4.
- [6] Hafeez M, Ansari A, Parveen S, Salamat A, Aijaz A. Frequency of intrahepatic cholestasis of pregnancy in Punjab Pakistan: A single centre study. *J Pak Med Assoc*. 2016 Feb 1;66(2):203-6.
- [7] Manjari VJ, Rastogi A, Anand M. A PROSPECTIVE STUDY ON PERINATAL OUTCOME OF OBSTETRIC CHOLESTASIS IN A TERTIARY CARE CENTRE. *Int J Acad Med Pharm*. 2024;6(3):802-6.
- [8] Westbrook RH, Dusheiko G, Williamson C. Pregnancy and liver disease. *Journal of hepatology*. 2016 Apr 1;64(4):933-45.
- [9] Bahadur A, Mundhra R, Kashibhatla J, Chawla L, Rajput R, Zaman R, Mahamood MM, Kumari P, Gupta R. Clinical spectrum and outcome of pregnancy with liver diseases—A prospective study. *Journal of Family Medicine and Primary Care*. 2022 Oct 1;11(10):6458-63.
- [10] Chang L, Wang M, Liu H, Meng Q, Yu H, Wu YM, Zhu Y. Pregnancy outcomes of patients with acute fatty liver of pregnancy: a case control study. *BMC pregnancy and childbirth*. 2020 Dec;20:1-8.
- [11] Sharma S, James MM. Case Report on Intrahepatic Cholestasis of Pregnancy. *Int. J. Nurs. Midwif. Res*. 2017;4:1.
- [12] Herrera CA, Manuck TA, Stoddard GJ, Varner MW, Esplin S, Clark EA, Silver RM, Eller AG. Perinatal outcomes associated with intrahepatic cholestasis of pregnancy. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2018 Jul 18;31(14):1913-20.
- [13] Senocak GN, Yilmaz EP. Maternal and fetal outcomes in pregnancies complicated by intrahepatic cholestasis. *The Eurasian Journal of Medicine*. 2019 Oct;51(3):270.
- [14] Senocak GN, Yilmaz EP. Maternal and fetal outcomes in pregnancies complicated by intrahepatic cholestasis. *The Eurasian Journal of Medicine*. 2019 Oct;51(3):270.
- [15] Brites D, Rodrigues CM, da Conceição Cardoso M, Graça LM. Unusual case of severe cholestasis of pregnancy with early onset, improved by ursodeoxycholic acid administration. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 1998 Feb 1;76(2):165-8.
- [16] Knox TA, Olans LB. Liver disease in pregnancy. *New England Journal of Medicine*. 1996 Aug 22;335(8):569-76.

- [17] Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomäki K. Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary diseases: a population-based study. *Hepatology*. 2006 Apr;43(4):723-8.
- [18] Brites D. Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. *Annals of hepatology*. 2002;1(1):20-8.
- [19] Castaño G, Lucangioli S, Sookoian S, Mesquida M, Lemberg A, Di Scala M, Franchi P, Carducci C, Tripodi V. Bile acid profiles by capillary electrophoresis in intrahepatic cholestasis of pregnancy. *Clinical science*. 2006 Apr 1;110(4):459-65.
- [20] Brouwers L, Koster MP, Page-Christiaens GC, Kemperman H, Boon J, Evers IM, Bogte A, Oudijk MA. Intrahepatic cholestasis of pregnancy: maternal and fetal outcomes associated with elevated bile acid levels. *American journal of obstetrics and gynecology*. 2015 Jan 1;212(1):100-e1.
- [21] Zecca E, De Luca D, Baroni S, Vento G, Tiberi E, Romagnoli C. Bile acid-induced lung injury in newborn infants: a bronchoalveolar lavage fluid study. *Pediatrics*. 2008 Jan 1;121(1):e146-9.
- [22] Hills BA, Chen Y, Masters IB, Hills YC. Raised bile acid concentrations in SIDS lungs at necropsy. *Archives of disease in childhood*. 1997 Aug 1;77(2):120-3.
- [23] Glantz A, Marschall HU, Mattsson LÅ. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. *Hepatology*. 2004 Aug;40(2):467-74.
- [24] 1. Benjaminov FS, Heathcote J. Liver disease in pregnancy. *Official journal of the American College of Gastroenterology | ACG*. 2004 Dec 1;99(12):2479-88.
- [25] 2. Faulkes RE, Chauhan A, Knox E, Johnston T, Thompson F, Ferguson J. chronic liver disease and pregnancy. *Alimentary pharmacology & therapeutics*. 2020 Aug;52(3):420-9.
- [26] 3. Wolf JL. Liver disease in pregnancy. *Medical Clinics of North America*. 1996 Sep 1;80(5):1167-87.